Russell Investments Group Ltd. Purchases New Holdings in Immatics N.V. $IMTX

Key Points

• Russell Investments Group Ltd. has acquired a new position in Immatics N.V., purchasing 95,383 shares valued at approximately $430,000, representing about 0.08% ownership of the company.
• Immatics reported a loss of $0.66 EPS for the last quarter, which was lower than the consensus estimate of ($0.38), and the firm had a revenue of only $6.48 million compared to expectations of $13.05 million.
• Analyst ratings for Immatics show a trend with Zacks Research downgrading the stock from "hold" to "strong sell", while Deutsche Bank initiated coverage with a "buy" rating and a target price of $10.00.

Russell Investments Group Ltd. acquired a new stake in shares of Immatics N.V. (NASDAQ:IMTX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 95,383 shares of the company's stock, valued at approximately $430,000. Russell Investments Group Ltd. owned about 0.08% of Immatics at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Bank of America Corp DE boosted its position in Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock valued at $25,000 after purchasing an additional 2,231 shares during the last quarter. Intellectus Partners LLC acquired a new stake in Immatics during the first quarter valued at $70,000. Forefront Analytics LLC raised its holdings in Immatics by 42.3% during the fourth quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock valued at $113,000 after buying an additional 4,731 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in Immatics by 94.5% during the first quarter. Exchange Traded Concepts LLC now owns 25,580 shares of the company's stock valued at $115,000 after buying an additional 12,425 shares in the last quarter. Finally, Graham Capital Management L.P. bought a new position in Immatics during the fourth quarter valued at about $130,000. Institutional investors and hedge funds own 64.41% of the company's stock.

Immatics Price Performance

Shares of NASDAQ IMTX traded down $0.01 during trading hours on Thursday, hitting $5.44. 219,885 shares of the company's stock were exchanged, compared to its average volume of 769,198. Immatics N.V. has a 1-year low of $3.30 and a 1-year high of $13.09. The stock has a market capitalization of $661.23 million, a price-to-earnings ratio of -8.36 and a beta of 1.02. The company's 50-day moving average price is $5.93 and its 200-day moving average price is $5.21.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.28). Immatics had a negative net margin of 59.29% and a negative return on equity of 15.60%. The firm had revenue of $6.48 million for the quarter, compared to the consensus estimate of $13.05 million. On average, research analysts expect that Immatics N.V. will post -0.72 earnings per share for the current year.

Wall Street Analyst Weigh In

IMTX has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft initiated coverage on Immatics in a report on Wednesday, May 28th. They set a "buy" rating and a $10.00 target price on the stock. Wall Street Zen lowered Immatics from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. Finally, Zacks Research lowered Immatics from a "hold" rating to a "strong sell" rating in a report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $14.67.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.